3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
8
Triple Negative Breast Neoplasms
6
Head and Neck Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Melanoma
5
Urinary Bladder Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
4
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Carcinoma, Merkel Cell
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Pathologic Complete Response
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
Trastuzumab
5
Carboplatin
5
Docetaxel
4
pertuzumab
3
Paclitaxel
3
Cyclophosphamide
3
pembrolizumab
2
Epirubicin
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
taxane
1
talazoparib
1
sarilumab
1
pyrotinib
1
pirarubicin
1
pexidartinib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
cemiplimab
×
Breast
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled